BRAin Cancer and Exercise (BRACE) Study.

Not Applicable

Completed

• Conditions: Brain Cancer; Cancer - Brain

• Registration Number: ACTRN12617001577303
• Lead Sponsor: Haematology & Oncology Clinics of Australia Research Centre Ltd (Trading as Icon Cancer Foundation)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-11-24
• Study Completion: 2020-07-21
• Last Update Posted: 16 February 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

1.People with a diagnosis of primary or recurrent malignant brain tumour (i.e. brain cancer e.g. gliomas (astrocytomas, glioblastomas, oligodendrogliomas, ependymomas and mixed cell type gliomas)). Patients with recurrent brain cancer are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. .
2.Age 18 years or older
3.Eastern Cooperative Oncology Group (ECOG) status 0-2.
4.Willing and able to comply with all study requirements, including the exercise intervention, timing and/or nature of required assessments.
5.Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements.
6.Anticipated survival of a minimum of 12 months, as assessed by the treating clinician (e.g. medical oncologist, radiation oncologist, or surgeon).
7.If radiotherapy was received, they are between 12 and 26 weeks post-radiotherapy (receipt of oral chemotherapy during this period is allowed).
8.Signed written informed consent.
9.Deemed suitable to participate in the study by treating clinician.

Exclusion Criteria

1.Diagnosis of secondary brain cancer, or brain cancer recurrence within the first two years of definitive primary treatment.
2.Diagnosis of central nervous system lymphoma.
3.History of another malignancy within 2 years prior to registration. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. Patients with a diagnosis of basal cell carcinoma and squamous cell carcinomas and pre-malignant carcinomas (e.g. in situ) are also eligible.
4.Concurrent illness, including severe infection or unstable angina that may jeopardise the ability of the patient to undergo the exercise intervention outlined in this protocol with reasonable safety.
5.Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol, as determined by their treating clinician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified